Redwood Investment Management LLC Sells 1,382 Shares of Catalent, Inc. (NYSE:CTLT)

Redwood Investment Management LLC decreased its position in Catalent, Inc. (NYSE:CTLT) by 14.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 8,101 shares of the company’s stock after selling 1,382 shares during the quarter. Redwood Investment Management LLC’s holdings in Catalent were worth $489,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Millennium Management LLC lifted its position in Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the period. Alpine Associates Management Inc. boosted its stake in Catalent by 3.4% in the third quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock valued at $129,082,000 after acquiring an additional 69,875 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Catalent by 14.9% in the second quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock valued at $108,559,000 after acquiring an additional 250,999 shares during the last quarter. Bank of Montreal Can raised its position in shares of Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after acquiring an additional 1,169,044 shares during the last quarter. Finally, Marshall Wace LLP raised its position in shares of Catalent by 5.1% during the 2nd quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock valued at $100,818,000 after acquiring an additional 86,533 shares during the last quarter.

Insider Buying and Selling

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CTLT has been the subject of a number of recent analyst reports. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Monday, December 2nd. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

Shares of CTLT opened at $61.84 on Friday. The firm has a market cap of $11.22 billion, a P/E ratio of -27.36, a PEG ratio of 2.45 and a beta of 1.15. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $62.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm’s 50 day moving average price is $60.07 and its two-hundred day moving average price is $58.69.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm posted ($0.10) earnings per share. The company’s revenue was up 4.2% compared to the same quarter last year. On average, analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.